75% of Adults Overweight or Obese; Global Diabetes Tx Lacking; Hidden Bone Data?

Three-fourths of U.S. adults are now overweight or have obesity, with nearly 260 million predicted to have overweight or obesity by 2050. (The Lancet)

According to another study in The Lancet, almost 60% of the over 800 million adults living with diabetes across the globe didn’t receive treatment.

A Swedish cohort study of kids with type 1 diabetes showed that poor glycemic control was tied to shorter height in adulthood. (Journal of Clinical Endocrinology & Metabolism)

Novo Nordisk will gradually stop production of insulin pens and instead shift focus to making its GLP-1 injectables, the drugmaker said. (Reuters)

In the 12-patient phase III VENTURE trial, the melanocortin-4 receptor agonist setmelanotide (Imcivree) yielded an 18% average change in body mass index by 52 weeks among children ages 2 to 5 years with rare genetic obesity. Maker Rhythm Pharmaceuticals sent the data to the FDA looking to expand the drug’s label to this younger group of kids. (Lancet Diabetes & Endocrinology)

For older adults on long-term statin therapy, SGLT2 inhibitors were associated with a lower risk of rhabdomyolysis compared with DPP-4 inhibitors in a case-control study. (JAMA Network Open)

Telehealth company Hims & Hers Health launched a new GLP-1 supply tracker, in which patients can share details about their challenges finding weight loss and diabetes drugs.

Experts warned about the “chilling” effect of the Texas attorney general suing doctors over gender-affirming care. (Salon)

Though published 9 months ago, a newly discovered hidden tab in an Excel spreadsheet of phase I data on Amgen’s investigational obesity drug maridebart cafraglutide revealed that patients on the highest dose lost around 4% of their bone mineral density across 12 weeks of treatment. However, Amgen said in a statement that the study findings “do not suggest any bone safety concern.” (FierceBiotech)

In a JAMA viewpoint on the high discontinuation rates of GLP-1 receptor agonists, researchers said that “quantifying whether short-term therapy results in some enduring benefit, a return to pretreatment cardiovascular risk, or rebound risk in excess of baseline risk should be a priority.”

A federal appeals court ruled that an Indiana law banning gender-affirming care for minors should remain in effect. (The Hill)

People diagnosed with type 2 diabetes at a younger age may have a higher risk of developing dementia compared with those diagnosed later in life, especially for those with obesity. (PLOS One)